132 related articles for article (PubMed ID: 7928303)
1. Independent and synergistic effect of interleukin-2 and prolactin on development of T- and NK-derived LAK effectors.
Cesano A; Oberholtzer E; Contarini M; Geuna M; Bellone G; Matera L
Immunopharmacology; 1994; 28(1):67-75. PubMed ID: 7928303
[TBL] [Abstract][Full Text] [Related]
2. Role of prolactin in the in vitro development of interleukin-2-driven anti-tumoural lymphokine-activated killer cells.
Matera L; Bellone G; Lebren JJ; Kelly PA; Hooghe Peters EL; Di Celle PF; Foa R; Contarini M; Avanzi G; Asnaghi V
Immunology; 1996 Dec; 89(4):619-26. PubMed ID: 9014831
[TBL] [Abstract][Full Text] [Related]
3. Prolactin response of NK cells, but not of LAK cells, is deficient in patients with carcinoma of oral cavity and during aging.
Chakraborty A; Chakraborty NG; Chattopadhyay U
Int J Cancer; 1996 Mar; 66(1):65-9. PubMed ID: 8608969
[TBL] [Abstract][Full Text] [Related]
4. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
[TBL] [Abstract][Full Text] [Related]
5. Prolactin increases the susceptibility of primary leukemia cells to NK and LAK effectors.
Oberholtzer E; Contarini M; Veglia F; Cossarizza A; Franceschi C; Geuna M; Provinciali M; Di Stefano G; Sissom J; Brizzi MF; Pegoraro L; Matera L
Adv Neuroimmunol; 1996; 6(3):233-47. PubMed ID: 8968423
[TBL] [Abstract][Full Text] [Related]
6. Role of prolactin in the modulation of NK and LAK cell activity after short- or long-term morphine administration in neoplastic patients.
Provinciali M; Di Stefano G; Stronati S; Raffaeli W; Pari G; Fabris N
Int J Immunopharmacol; 1996 Oct; 18(10):577-86. PubMed ID: 9080251
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of human NK cell and LAK cell cytotoxicity and differentiation by PGE2.
Leung KH
Cell Immunol; 1989 Oct; 123(2):384-95. PubMed ID: 2507171
[TBL] [Abstract][Full Text] [Related]
8. Functional interactions of IL2 and TNF in the differentiation of LGL into LAK effectors.
Blay JY; Bertoglio J; Fradelizi D; Chouaib S
Int J Cancer; 1989 Oct; 44(4):598-604. PubMed ID: 2793231
[TBL] [Abstract][Full Text] [Related]
9. Normal development of lymphokine activated killing (LAK) in peripheral blood lymphocytes from hyperprolactinemic patients.
Matera L; Ciccarelli E; Muccioli G; Cesano A; Grottoli S; Oberholtzer E; Camanni F
Int J Immunopharmacol; 1992 Oct; 14(7):1235-40. PubMed ID: 1452408
[TBL] [Abstract][Full Text] [Related]
10. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
[TBL] [Abstract][Full Text] [Related]
11. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition.
Mueller EA; Anderer FA
Cancer Res; 1990 Jun; 50(12):3646-51. PubMed ID: 1692765
[TBL] [Abstract][Full Text] [Related]
12. Intracellular calcium changes associated with in vitro lymphokine-activated killer and natural killer cell cytotoxicity.
Burkey BB; Omann GM; Wolf GT
Arch Otolaryngol Head Neck Surg; 1991 Nov; 117(11):1281-6. PubMed ID: 1747234
[TBL] [Abstract][Full Text] [Related]
13. Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii.
Subauste CS; Dawson L; Remington JS
J Exp Med; 1992 Dec; 176(6):1511-9. PubMed ID: 1460415
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
Kaufmann Y; Levanon M; Davidsohn J; Ramot B
J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395
[TBL] [Abstract][Full Text] [Related]
15. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
16. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro.
Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T
Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536
[TBL] [Abstract][Full Text] [Related]
17. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
18. Leukoregulin up-regulation of tumor cell sensitivity to natural killer and lymphokine-activated killer cell cytotoxicity.
Furbert-Harris PM; Evans CH
Cancer Immunol Immunother; 1989; 30(2):86-91. PubMed ID: 2688871
[TBL] [Abstract][Full Text] [Related]
19. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
[TBL] [Abstract][Full Text] [Related]
20. The presence and cytotoxicity of CD16+ CD2- subset from PBL and NK cells in long-term IL-2 cultures enhanced by Prothymosin-alpha.
Cordero OJ; Sarandeses C; López-Rodríguez JL; Nogueira M
Immunopharmacology; 1995 Apr; 29(3):215-23. PubMed ID: 7542644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
